[1] دانائی‌فر، کیمیا، عبدوس، مجید، کرمی، ماندانا. آنالیز اندازه ذرات و بار سطحی نانو سیستم های دارویی بوسیله پراکنش دینامیکی در درمان سرطان. دنیای نانو، ۱۴۰۳؛ ۲۰(۷۶): ۷۳-۵۲.
[2] کرمی، محمد حسین، عبدوس، مجید، کرمی، ماندانا. آنالیز اندازه ذرات و بار سطحی نانو سیستم های دارویی بوسیله پراکنش دینامیکی در درمان سرطان. دنیای نانو، ۱۴۰۳؛ ۲۰(۷۴): ۱۴-۱.
[3] Yusuf A, Almotairy ARZ, Henidi H, Alshehri OY, Aldughaim MS. Nanoparticles as drug delivery systems: a review of the implication of nanoparticles’ physicochemical properties on responses in biological systems. Polymers. 2023; 15(7): 1596.
[4] Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov. 2014; 13(9): 655–672.
[5] Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res. 2016; 33(10): 2373–2387.
[6] Thapa RK, Kim JO. Nanomedicine-based commercial formulations: current developments and future prospects. J Pharm Investig. 2023; 53(1): 19–33.
[7] Plotkin SA. History of vaccination. Proc Natl Acad Sci U S A. 2014; 111(34): 12283–12287.
[8] Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Immunol. 2011; 12(6): 509–517.
[9] Zhao L, Wang H, Li M. Recent advances in understanding T-cell memory and vaccine-induced protection. Front Immunol. 2022; 13: 972134.
[10] Kaur G, Pawaiya A, Kaur D, Pasricha S, Rani P. Nanovaccines: A revolutionary paradigm in immunization. Int J Pharm Sci. 2025; 3(4): 1271–1289.
[11] Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines — a new era in vaccinology. Nat Rev Drug Discov. 2018; 17(4): 261–279.
[12] Palmieri V, Caracciolo G. Tuning the immune system by nanoparticle-biomolecular corona. Nanoscale Adv. 2022; 4(12): 3300–3308.
[13] Mohammadi E, Akbari S, Akbari A. Advanced nanovaccine delivery systems: from nanobiomaterials to manufacturing processes. NanoSci Technol. 2024; 15: 17–32.
[14] Zhao L, Seth A, Wibowo N, Zhao CX, Mitter N, Yu C, Middelberg APJ. Nanoparticle vaccines. Vaccine. 2021; 39(3): 327–337.
[15] Shetty S, Alvarado PC, Pettie D, Collier JH. Next-generation Vaccine Development with nanomaterials: recent advances, possibilities, and challenges. Annu Rev Biomed Eng. 2024; 26(1): 273-306.
[16] Liu L, Kim JH, Li Z, Sun M, Northen T, Tang J, et al. PEGylated lipid screening, composition optimization, and structure-activity relationship determination for lipid nanoparticle-mediated mRNA delivery. Nanoscale. 2025; 18: 4212–4229.
[17] Zhai L, Lai H. Advances in nanoparticle-based vaccine delivery systems. J Control Release. 2021; 332: 598–607.
[18] Lynn GM, et al. Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly. Nat Biotechnol. 2020; 38(3): 320–332.
[19] Irvine DJ, Read BJ. Shaping humoral immunity to vaccines through antigen-displaying nanoparticles. Curr Opin Immunol. 2020; 65: 1–6.
[20] Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine BNT162b2 elicits human antibody and TH1 T cell responses. Nature. 2020; 586(7830): 594–599.
[21] Sharma S, Singh A, Kumar R, Mehta A. Polymeric nanoparticles in vaccine delivery: advances, challenges, and future prospects. J Control Release. 2022; 348: 51–80.
[22] Xu Z, Shen C, Hou Y, Gao H, Liu J, Li Y. Chitosan-based nanocarriers for oral vaccine delivery.
[23] Zhang C, Zhang L, Yu W, He Y, Wang Y, Zhang N. Advances in polymer-based nanovaccines for cancer immunotherapy. Biomaterials. 2021; 268: 120606.
[24] Jalalifar M, et al. Chitosan nanoparticles in oral vaccine delivery. Int J Biol Macromol. 2021; 183: 246–260.
[25] Zare M, Badruddoza AZM. Nanoparticle-based vaccines: A new era in vaccinology. Trends Biotechnol. 2021; 39(10): 1050–1065.
[26] Duman H, Akdaşçı E, Eker F, Bechelany M, Karav S. Gold nanoparticles: multifunctional properties, synthesis, and future prospects. Nanomaterials. 2024; 14(22): 1805.
[27] Huang H, Liu R, Yang J, Dai J, Fan S, et al. Gold nanoparticles: construction for drug delivery and application in cancer immunotherapy. Pharmaceutics. 2023; 15(7): 1868.
[28] Abbas HA, et al. Gold nanoparticle monolayer-based field-effect molecular sensors. Adv Electron Mater. 2024; 10(6): 2400363.
[29] Chen G, Roy I, Yang C, Prasad PN. Nanochemistry and nanomedicine for nanoparticle-based diagnostics and therapy. Chem Rev. 2016; 116(5): 2826–2885.
[30] De Souza TA, Dos Santos MS, Soares SF, Hotza D, Grecco CH. Silver nanoparticles functionalized textile against SARS-CoV-2: Antiviral activity of the capping agents. J Mater Sci. 2025; 60(2): 1450–1466.
[31] Sargsian A, Koutsoumpou X, Girmatsion H, Egil C, Buttiens K, et al. Silver nanoparticle induced immunogenic cell death can improve immunotherapy. J Nanobiotechnol. 2024; 22: 691.
[32] Buchhorn de Freitas S, Seixas Neto ACP, Panagio LA, Collares TV, Kömmling Seixas F, et al. Biogenic silver nanoparticle as an adjuvant in an S1 subunit recombinant vaccine. Braz J Microbiol.
[33] Kaur G, Pawaiya A, Kaur D, Pasricha S, Rani P. Nanovaccines: A revolutionary paradigm in immunization. Int J Pharm Sci.
[34] Fatima R, Katiyar P, Kushwaha K. Recent advances in mesoporous silica nanoparticle: synthesis, drug loading, release mechanisms, and diverse applications. Front Nanotechnol. 2025; 7: 1564188.
[35] López MD, Yang R, Chang J. Silica-Coated Quantum Dots Enhance Delivery and Immunogenicity of Influenza Antigens. ACS Appl Nano Mater. 2023; 6(5): 3945–3953.
[36] Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021; 6: 1078–1094.
[37] Ghazi R, Ibrahim TK, Nasir JA, Gai S, Ali G, Boukhris I, Rehman Z. Iron oxide based magnetic nanoparticles for hyperthermia, MRI and drug delivery applications: a review. RSC Adv. 2025; 15: 11587–11616.
[38] Riaz S, Ali S, Summer M, Akhtar U, Noor S, Haqqi R, Faroooq MA, Sardar I. Multifunctional magnetic nanoparticles for targeted drug delivery against cancer: mechanisms, applications, and tailoring strategies. Ann Biomed Eng. 2025; 53: 1291–1327.
[39] Rezaei M, Hosseini SN, Khavari-Nejad RA, Najafi F, Mahdavi M. HBs antigen and mannose loading on the surface of iron oxide nanoparticles in order to immuno-targeting: fabrication, characterization, cellular and humoral immunoassay. Artif Cells Nanomed Biotechnol. 2019; 47(1): 1543–1555.
[40] Liu Y, Hardie J, Zhang X, Rotello VM. Effects of engineered nanoparticles on the innate immune system. Semin Immunol. 2017; 34: 25–32.
[41] Chowdhury S, Toth I, Stephenson RJ. Dendrimers in vaccine delivery: recent progress and advances. Biomaterials. 2022; 280: 121303.
[42] Lynn GM, et al. Peptide-TLR-7/8a conjugate vaccines for nanoparticle self-assembly. Nat Biotechnol. 2020; 38(3): 320–332.
[43] Tarach P, Janaszewska A. Recent advances in preclinical research using PAMAM dendrimers for cancer gene therapy. Int J Mol Sci. 2021; 22(6): 2912.
[44] Rodríguez-Fonseca RA, Bello M, Rojas-Hernández S, et al. In silico and in vivo studies of gp120-HIV-derived peptides in complex with G4-PAMAM dendrimers. RSC Adv. 2020; 10(34): 20414–20426.
[45] Mahmood A, Ijaz H, Sarfraz RM, Zafar N, Zaman M, Azam M. Polymeric hydrogels and nanogels: classification, development and pharmaceutical applications. In: Hydrogels and Mucoadhesive and immunoenhancing properties. Int J Pharm. 2022; 613: 120413.
[46] Haddad HF, Roe EF, Collier JH. Expanding opportunities to engineer mucosal vaccination with biomaterials. Biomater Sci. 2023; 11(16): 1625–1647.
[47] Kim JY, Kim YI, Kim EH, et al. Intranasal administration of self-assembled nanogel vaccine induces protective immunity against respiratory viruses. J Control Release. 2023; 353: 765–776.
[48] Masarwy R, et al. Targeted CRISPR-Cas9 lipid nanoparticles elicit therapeutic genome editing. Adv Sci. 2025; 12(10): 2301530.
[49] Yoon HY, et al. Piperazine-derived bisphosphonate-based ionizable lipid nanoparticles enhance mRNA delivery. Angew Chem Int Ed. 2024; 63(2): e202314571.
[50] Abbas HA, et al. Gold nanoparticle monolayer-based field-effect molecular sensors. Adv Electron Mater. 2024; 10(6): 2400245.
[51] Hu J, Zhu L, Wu S, Ding S. Rapid and sensitive detection of influenza B virus employing nanocomposite spheres based on Ag-doped ZnIn2S4 quantum dots. Chemosensors. 2024; 12(4): 68.
[52] Liang Y, Mao G, Dai J, Ma Y. Biofunctionalized semiconductor quantum dots for virus detection. J Semicond.
[53] Chen G, Roy I, Yang C, Prasad PN. Nanochemistry and nanomedicine for nanoparticle-based diagnostics and therapy. Chem Rev. 2016; 116(5): 2826–2885.
[54] Monopoli MP, Åberg C, Salvati A, Dawson KA. Biomolecular coronas provide the biological identity of nanosized materials. Nat Nanotechnol. 2012; 7(12): 779–786.
[55] Bachmann MF, van Damme P, Lienert F, Schwarze TF. Virus-like particles: a versatile and effective vaccine platform. Expert Rev Vaccines. 2025; 24(1): 444–456.
[56] Ning W, Yan S, Song Y, Xu H, Zhang J, Wang X. Virus-like particle: a nano-platform that delivers cancer antigens to elicit an anti-tumor immune response. Front Immunol. 2025; 15: 1504124.
[57] شریعت نبوی، ناهیدالسادات، عالم‌زاده، عفت، عالم‌زاده، عصمت. ذرات شبه ویروسی و کاربرد آن در نانوزیست فناوری. دنیای نانو، ۱۴۰۳؛ ۲۰(۷۷): ۱۳۶-۱۲۶.
[58] Lin G, Wang J, Yang YG, Zhang Y, Sun T. Advances in dendritic cell targeting nano-delivery systems for induction of immune tolerance. Front Bioeng Biotechnol. 2023; 11: 1242126.
[59] Albanese A, Tang PS, Chan WCW. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng. 2012; 14: 1–16.
[60] Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines — a new era in vaccinology. Nat Rev Drug Discov. 2018; 17(4): 261–279.
[61] Dolgin E. The tangled history of mRNA vaccines. Nature. 2021; 597(7876): 318–324.
[62] Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021; 6: 1078–1094.
[63] Verbeke R, Lentacker I, De Smedt SC, Dewitte H. Three decades of messenger RNA vaccine development. Nano Today. 2019; 28: 100766.
[64] Jackson LA, et al. An mRNA vaccine against SARS-CoV-2 — preliminary report. N Engl J Med. 2020; 383: 1920–1931.
[65] Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N Engl J Med. 2020; 383(16): 1544–1555.
[66] Sahin U, et al. COVID-19 vaccine BNT162b2 induces protective immunity. Nature. 2020; 586(7830): 594–599.
[67] Polack FP, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020; 383(27): 2603–2615.
[68] Ghosh Majumdar A, Pany B, Parua SS, Mukherjee D, Panda A, Mohanty M, et al. Stimuli-responsive nanogel/microgel hybrids as targeted drug delivery systems: a comprehensive review. BioNanoScience. 2024; 14: 3496–3521.
[69] Yang H, Li J, Song C, Li H, Luo Q, Chen M. Emerging Gene Therapy Based on Nanocarriers: A Promising Therapeutic Alternative for Cardiovascular Diseases and a Novel Strategy in Valvular Heart Disease. Int J Mol Sci. 2025; 26(4): 1743.
[70] Zhang Y, Wang J, Xing H, Liu C, Zha W, Dong S, et al. Enhanced immunogenicity induced by mRNA vaccines with various lipid nanoparticles as carriers for SARS-CoV-2 infection. J Mater Chem B.
[71] Liu J, Wang T, Dong J, Lu Y. The blood-brain barriers: novel nanocarriers for central nervous system diseases. J Nanobiotechnol. 2025; 23: 146.
[72] Mironova M, Ghany MG. Hepatitis B Vaccine: Four Decades on. Vaccines. 2024; 12(4): 439.
[73] Datoo MS, et al. Efficacy of R21/Matrix-M malaria vaccine: a phase 2b trial. Lancet. 2021; 397(10287): 1809-1818.
[74] Alam S, Hafeez A, Ansari JA, Kaushal V, Kushwaha SP. Intranasal delivery of drug-loaded polymeric nanomicelles for brain targeting: a comprehensive review. J Nanopart Res. 2025; 27: 173.
[75] Zeng Y, Yin Y, Xu J, Su R, Zhang S, Han F, et al. Novel adjuvant delivery system constructed by alum-emulsion hybrid nanoparticles with TLR9 agonists boosts vaccine immunity. J Nanobiotechnol. 2025; 23: 472.
[76] Zhao L, Seth A, Wibowo N, et al. Nanoparticle vaccines. Vaccine. 2021; 39(3): 327-337.
[77] Nooraei S, Bahrulolum H, Hoseini ZS, Katalani C, Hajizade A, Easton AJ, Ahmadian G. Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J Nanobiotechnol. 2021; 19: 59.
[78] Choi J, Kim J, Cheong H. Functionalized nanoparticles for mucosal vaccine delivery. Adv Healthc Mater. 2023; 12(1): 2201732.
[79] Khehra N, Padda I, Jaferi U, Atwal H, Narain S, Parmar MS. Tozinameran (BNT162b2) vaccine: the journey from preclinical research to clinical trials and authorization. AAPS PharmSciTech. 2021; 22: 172.
[80] WHO Strategic Advisory Group of Experts (SAGE). Background document on the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19. WHO Publications; 2021.
[81] Zhang Y, Wang Y, Xing H, et al. Enhanced immunogenicity induced by mRNA vaccines with various lipid nanoparticles as carriers for SARS-CoV-2 infection. J Mater Chem B. 2023; 11(34): 7454-7465.
[82] El Sahly HM, Baden LR, Essink B, et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med. 2021; 385: 1774-1785.
[83] Amiri S, Rasekh S, Moezzi SMI, Seifi N, Fatemi SA, et al. Prophylactic vaccines against HPV-caused cervical cancer: novel vaccines are still demanded. Infect Agents Cancer. 2025; 20: 16.
[84] Centers for Disease Control and Prevention (CDC). HPV Vaccine Composition and Efficacy. CDC Website; 2021.
[85] Kingston NJ, Walsh R, Hammond R, Joe CCD, Lovrecz G, et al. Immunogenicity of wild type and mutant hepatitis B surface antigen virus-like particles (VLPs) in mice with pre-existing immunity against the wild type vector. Viruses. 2023; 15(2): 313.
[86] World Health Organization. WHO recommends R21/Matrix-M malaria vaccine for children at risk. WHO News Release. 2023 Oct 2.
[87] Novavax, Inc. Results from Novavax NanoFlu Influenza Vaccine Phase 3 Clinical Trial Published in The Lancet Infectious Diseases. Novavax Press Release. 2021 Sep 23.
[88] Sahin U, Oehm P, Derhovanessian E, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020; 585: 107-112.
[89] Shetty S, Cordero Alvarado P, Pettie D, Collier JH. Next-generation vaccine development with nanomaterials. Annu Rev Biomed Eng. 2024; 26: 273-306.
[90] Saleemi MA, Zhang Y, Zhang G. Current progress in novel adjuvant nano-vaccine-induced protective immune responses. Pathogens. 2024; 13(6): 441.
[91] Sargsian A, Koutsoumpou X, Girmatsion H, et al. Silver nanoparticle induced immunogenic cell death can improve immunotherapy. J Nanobiotechnol. 2024; 22: 691.
[92] Garai A, Diethör S, Mayr F, Scharber MC, Sariciftci NS, Klar TA. Redox-chemical electron storage on sub-5 nm gold nanoparticles compromised by Coulomb repulsion. J Phys Chem C. 2025; 129(13): 6322-6331.
[93] Dos Santos LMG, Medeiros RJ, Maciel-Magalhães M, et al. Unravelling the effects of silver nanoparticles on textiles: a comprehensive toxicological and quantitative analysis. Health Nanotechnology. 2025; 1: 6.
[94] Masarwy R, et al. Targeted CRISPR-Cas9 lipid nanoparticles elicit therapeutic genome editing. Adv Sci. 2025; 12(10): 2301530.
[95] Yoon IC, Xue L, Chen Q, Liu J, Xu J, et al. Piperazine-derived bisphosphonate-based ionizable lipid nanoparticles enhance mRNA delivery to the bone microenvironment. Angew Chem Int Ed. 2024; 63(2): e202415389.
[96] Lapsed G. Ensuring safety and regulation of nanomaterials: current standards and future directions. J Nanosci Curr Res. 2024; 9(3): 1-12.
